Latest Breaking News On - ஆராய்ச்சி அறிக்கை ஆன் - Page 1 : comparemela.com

Leerink Partners Thinks Axsome Therapeutics Stock is Going to Recover

Markets Leerink Partners analyst Marc Goodman maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) on April 26. The company’s shares closed last Wednesday at $59.74, close to its 52-week low of $50.05. According to TipRanks.com, Goodman is a 3-star analyst with an average return of 3.2% and a 47.7% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals. Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $144.00, representing a 136.7% upside. In a report issued on April 26, Mizuho Securities also maintained a Buy rating on the stock with a $118.00 price target.

New yorkUnited statesMarc goodmanSatsuma pharmaceuticalsAxsome therapeutics incResearch report onBiohaven pharmaceutical holding coLeerink partnersAxsome therapeuticsResearch reportIntra cellular therapiesStrong buyMizuho securitiesHerriot tabuteauபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்

Castle Biosciences (CSTL) Receives a Buy from Leerink Partners

Markets Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) on April 27. The company’s shares closed last Wednesday at $68.77. According to TipRanks.com, Souda is a 5-star analyst with an average return of 27.0% and a 73.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, AbCellera Biologics, and Twist Bioscience. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $88.67 average price target, a 26.3% upside from current levels. In a report issued on April 27, Canaccord Genuity also maintained a Buy rating on the stock with a $94.00 price target.

Puneet soudaCanaccord genuityCastle biosciencesAbcellera biologicsDerekj maetzoldCastle biosciences incResearch report onLeerink partnersResearch reportStrong buyகானக்கோர்ட் உண்மையானதுகோட்டை உயிர் அறிவியல்கோட்டை உயிர் அறிவியல் இன்க்ஆராய்ச்சி அறிக்கை ஆன்ஆராய்ச்சி அறிக்கைவலுவான வாங்க

Reata Pharmaceuticals (RETA) Receives a Buy from Leerink Partners

Markets Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Reata Pharmaceuticals (RETA – Research Report) on April 26. The company’s shares closed last Wednesday at $103.79. According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 15.9% and a 49.6% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Reata Pharmaceuticals with a $186.33 average price target, implying an 82.4% upside from current levels. In a report issued on April 26, Barclays also initiated coverage with a Buy rating on the stock with a $155.00 price target.

W christian wigleyPhilipj thomasJoseph schwartzJonathanm graffReata pharmaceuticalsReata pharmaceuticals incResearch report onCrinetics pharmaceuticalsLeerink partnersResearch reportApplied molecular transportUltragenyx pharmaceuticalStrong buyWaldemar priebeJef karel de brabanderஜோசப் ஸ்க்வார்ட்ஸ்

Leerink Partners Thinks Provention Bio s Stock is Going to Recover

Leerink Partners Thinks Provention Bio s Stock is Going to Recover
markets.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from markets.co Daily Mail and Mail on Sunday newspapers.

Thomas smithProvention bioProvention bio incEledon pharmaceuticalsMadrigal pharmaceuticalsResearch report onBiopharma holdingsLeerink partnersResearch reportConnect biopharma holdingsStrong buyFrancisco leonAshleigh palmerதாமஸ் ஸ்மித்மாட்ரிகல் மருந்துகள்ஆராய்ச்சி அறிக்கை ஆன்

Cellectis SA (CLLS) Receives a Buy from Robert W Baird

Cellectis SA (CLLS) Receives a Buy from Robert W Baird
analystratings.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from analystratings.com Daily Mail and Mail on Sunday newspapers.

France generalDavidj sourdiveRobertw bairdBrian skorneyWilliam blairVertex pharmaceuticalsResearch report onResearch reportEiger biopharmaceuticalsStrong buyபிரான்ஸ் ஜநரல்வில்லியம் பிளேயர்வெர்டெக்ஸ் மருந்துகள்ஆராய்ச்சி அறிக்கை ஆன்ஆராய்ச்சி அறிக்கைஈகர் உயிர் மருந்துகள்